Anti-high mobility group box-1 antibody therapy for traumatic brain injury

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) is one of the major causes of death and aftereŠects in young individuals worldwide; however, efficient therapies for TBI are lacking at present. High mobility group box-1 (HMGB-1), which is recognized as a representative of danger-associated molecular patterns (DAMPs), plays an important role in triggering inflammatory responses in many types of diseases.We presented the involvement of HMGB-1 in TBI and evaluated the ability of intravenously administered neutralizing anti-HMGB-1 monoclonal antibody (mAb) to attenuate brain injury. Anti-HMGB-1 mAb may provide a novel and eŠective therapy for TBI by protecting against blood brain barrier disruption and reducing the inflammatory responses induced by HMGB-1.

Original languageEnglish
Pages (from-to)701-705
Number of pages5
JournalYakugaku Zasshi
Volume134
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Antibodies
Monoclonal Antibodies
Therapeutics
Blood-Brain Barrier
Brain Injuries
Cause of Death
Traumatic Brain Injury

Keywords

  • High mobility group box-1
  • Secondary injury
  • Traumatic brain injury

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Medicine(all)

Cite this

Anti-high mobility group box-1 antibody therapy for traumatic brain injury. / Okuma, Yu; Date, Isao; Nishibori, Masahiro.

In: Yakugaku Zasshi, Vol. 134, No. 6, 2014, p. 701-705.

Research output: Contribution to journalArticle

@article{0a74c80414a24cac82cf4bfe37979b4b,
title = "Anti-high mobility group box-1 antibody therapy for traumatic brain injury",
abstract = "Traumatic brain injury (TBI) is one of the major causes of death and aftereŠects in young individuals worldwide; however, efficient therapies for TBI are lacking at present. High mobility group box-1 (HMGB-1), which is recognized as a representative of danger-associated molecular patterns (DAMPs), plays an important role in triggering inflammatory responses in many types of diseases.We presented the involvement of HMGB-1 in TBI and evaluated the ability of intravenously administered neutralizing anti-HMGB-1 monoclonal antibody (mAb) to attenuate brain injury. Anti-HMGB-1 mAb may provide a novel and eŠective therapy for TBI by protecting against blood brain barrier disruption and reducing the inflammatory responses induced by HMGB-1.",
keywords = "High mobility group box-1, Secondary injury, Traumatic brain injury",
author = "Yu Okuma and Isao Date and Masahiro Nishibori",
year = "2014",
doi = "10.1248/yakushi.13-00255-2",
language = "English",
volume = "134",
pages = "701--705",
journal = "Yakugaku Zasshi",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "6",

}

TY - JOUR

T1 - Anti-high mobility group box-1 antibody therapy for traumatic brain injury

AU - Okuma, Yu

AU - Date, Isao

AU - Nishibori, Masahiro

PY - 2014

Y1 - 2014

N2 - Traumatic brain injury (TBI) is one of the major causes of death and aftereŠects in young individuals worldwide; however, efficient therapies for TBI are lacking at present. High mobility group box-1 (HMGB-1), which is recognized as a representative of danger-associated molecular patterns (DAMPs), plays an important role in triggering inflammatory responses in many types of diseases.We presented the involvement of HMGB-1 in TBI and evaluated the ability of intravenously administered neutralizing anti-HMGB-1 monoclonal antibody (mAb) to attenuate brain injury. Anti-HMGB-1 mAb may provide a novel and eŠective therapy for TBI by protecting against blood brain barrier disruption and reducing the inflammatory responses induced by HMGB-1.

AB - Traumatic brain injury (TBI) is one of the major causes of death and aftereŠects in young individuals worldwide; however, efficient therapies for TBI are lacking at present. High mobility group box-1 (HMGB-1), which is recognized as a representative of danger-associated molecular patterns (DAMPs), plays an important role in triggering inflammatory responses in many types of diseases.We presented the involvement of HMGB-1 in TBI and evaluated the ability of intravenously administered neutralizing anti-HMGB-1 monoclonal antibody (mAb) to attenuate brain injury. Anti-HMGB-1 mAb may provide a novel and eŠective therapy for TBI by protecting against blood brain barrier disruption and reducing the inflammatory responses induced by HMGB-1.

KW - High mobility group box-1

KW - Secondary injury

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=84922235551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922235551&partnerID=8YFLogxK

U2 - 10.1248/yakushi.13-00255-2

DO - 10.1248/yakushi.13-00255-2

M3 - Article

C2 - 24882644

AN - SCOPUS:84922235551

VL - 134

SP - 701

EP - 705

JO - Yakugaku Zasshi

JF - Yakugaku Zasshi

SN - 0031-6903

IS - 6

ER -